Sign In
Buy VTGN
VistaGen Therapeutics Earnings Calls
| Release date | Aug 06, 2026 |
| EPS estimate | -$0.365 |
| EPS actual | - |
| Revenue estimate | 500K |
| Revenue actual | - |
| Expected change | +/- 8.88% |
| Release date | Jun 15, 2026 |
| EPS estimate | -$0.420 |
| EPS actual | -$0.370 |
| EPS Surprise | 11.90% |
| Revenue estimate | 399.9K |
| Revenue actual | 464K |
| Revenue Surprise | 16.03% |
| Release date | Feb 12, 2026 |
| EPS estimate | -$0.510 |
| EPS actual | -$0.450 |
| EPS Surprise | 11.76% |
| Revenue estimate | 364.433K |
| Revenue actual | 303K |
| Revenue Surprise | -16.86% |
| Release date | Nov 13, 2025 |
| EPS estimate | -$0.510 |
| EPS actual | -$0.540 |
| EPS Surprise | -5.88% |
| Revenue estimate | 145.8K |
| Revenue actual | 258K |
| Revenue Surprise | 76.95% |
Last 4 Quarters for VistaGen Therapeutics
Below you can see how VTGN performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Nov 13, 2025 |
| Price on release | $3.80 |
| EPS estimate | -$0.510 |
| EPS actual | -$0.540 |
| EPS surprise | -5.88% |
| Date | Price |
|---|---|
| Nov 07, 2025 | $3.99 |
| Nov 10, 2025 | $3.98 |
| Nov 11, 2025 | $4.03 |
| Nov 12, 2025 | $4.07 |
| Nov 13, 2025 | $3.80 |
| Nov 14, 2025 | $3.80 |
| Nov 17, 2025 | $4.42 |
| Nov 18, 2025 | $4.63 |
| Nov 19, 2025 | $4.50 |
| 4 days before | -4.76% |
| 4 days after | 18.42% |
| On release day | 0% |
| Change in period | 12.78% |
| Release date | Feb 12, 2026 |
| Price on release | $0.545 |
| EPS estimate | -$0.510 |
| EPS actual | -$0.450 |
| EPS surprise | 11.76% |
| Date | Price |
|---|---|
| Feb 06, 2026 | $0.557 |
| Feb 09, 2026 | $0.561 |
| Feb 10, 2026 | $0.565 |
| Feb 11, 2026 | $0.573 |
| Feb 12, 2026 | $0.545 |
| Feb 13, 2026 | $0.506 |
| Feb 17, 2026 | $0.530 |
| Feb 18, 2026 | $0.516 |
| Feb 19, 2026 | $0.592 |
| 4 days before | -2.14% |
| 4 days after | 8.68% |
| On release day | -7.23% |
| Change in period | 6.36% |
| Release date | Jun 15, 2026 |
| Price on release | $0.573 |
| EPS estimate | -$0.420 |
| EPS actual | -$0.370 |
| EPS surprise | 11.90% |
| Date | Price |
|---|---|
| Jun 09, 2026 | $0.538 |
| Jun 10, 2026 | $0.535 |
| Jun 11, 2026 | $0.573 |
| Jun 12, 2026 | $0.576 |
| Jun 15, 2026 | $0.573 |
| Jun 16, 2026 | $0.690 |
| Jun 17, 2026 | $0.690 |
| Jun 18, 2026 | $0.670 |
| Jun 22, 2026 | $0.640 |
| 4 days before | 6.55% |
| 4 days after | 11.68% |
| On release day | 20.42% |
| Change in period | 18.98% |
| Release date | Aug 06, 2026 |
| Price on release | - |
| EPS estimate | -$0.365 |
| EPS actual | - |
| Date | Price |
|---|---|
| Jul 06, 2026 | $0.246 |
| Jul 07, 2026 | $0.237 |
| Jul 08, 2026 | $0.235 |
| Jul 09, 2026 | $0.249 |
| Jul 10, 2026 | $0.258 |
VistaGen Therapeutics Earnings Call Transcript Summary of Q1 2026
Vistagen reported progress in FY2026 Q1 focused on its intranasal pherine neuroscience pipeline. The lead candidate, fasedienol, is in late Phase III for acute treatment of social anxiety disorder (SAD); topline results from PALISADE-3 are expected in Q4 2025 and PALISADE-4 in H1 2026. The company believes success in either Phase III trial combined with prior positive PALISADE-2 results could establish substantial evidence of effectiveness to support a U.S. NDA for acute SAD. Enrollment remains active for both Phase III studies, with the company noting strong subject conversion into the open-label extension (OLE) and good retention. Vistagen is also advancing development plans for Itruvone (major depressive disorder) and PH80 (menopausal hot flashes), with a U.S. IND for PH80 planned for Q4 2025. Financially, R&D spend rose to $11.7M for the quarter (from $7.6M year-over-year) driven by PALISADE, G&A was $4.4M, net loss was $15.1M, and cash and equivalents stood at $63.2M as of June 30, 2025. Management emphasized the differentiated, nonsystemic profile and safety of pherines, ongoing KOL outreach, site oversight practices, and preparation for potential commercialization if results are positive.
